+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Inflammatory mediators in chronic inflammatory bowel diseases

Inflammatory mediators in chronic inflammatory bowel diseases

Klinische Wochenschrift 69(21-23): 981-987

Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases (IBD) of unknown etiology. They are characterized by an activation of intestinal mononuclear cells. Cytokines play a crucial role in the regulation of the functions of these cells. An increased synthesis of the cytokines interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF alpha), which are primarily synthesized by activated monocytes/macrophages has been described in patients with IBD. The synthesis of interleukin-2 (IL-2) and of interferon gamma (IFN gamma), which are produced by lymphocytes, on the other hand, has been found to be decreased. The published data are, however, not quite consistent. In patients with IBD there is not only a stimulation of the local cytokine production in the gut. The blood levels and the synthesis of the cytokines IL-1, IL-6 and TNF alpha by peripheral blood mononuclear cells are also increased, in particular in patients with Crohn's disease. Drugs, which are commonly used for the treatment of IBD impair the synthesis of these cytokines in monocytes/macrophages.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 040428113

Download citation: RISBibTeXText

PMID: 1798295

DOI: 10.1007/bf01645143

Related references

Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH. Zeitschrift für Gastroenterologie 44(6): 525-38; Discussion 539, 2006

Immune complexes and acute phase proteins in chronic inflammatory joint diseases chronic inflammatory bowel diseases parasitic diseases and lymphoma. European Journal of Clinical Investigation 12(2 Part 2): 22, 1982

Diagnosis in chronic inflammatory bowel diseases--report of the Austrian Chronic Inflammatory Bowel Disease Study Group. Acta Medica Austriaca 25(2): 37-43, 1998

Osteoporosis in chronic inflammatory bowel diseases--what is the value of fluoride therapy? Symposium: "Osteopenia, osteoporosis in chronic inflammatory bowel diseases". Saalfelden, 10 October 1998. Deutsche Medizinische Wochenschrift 123(51-52 Suppl Osteoporos): 1-4, 1999

Leucocyte Elastase in Chronic Inflammatory Bowel Diseases: A Marker of Inflammatory Activity?. Digestion 37(2): 88-95, 1987

Gut Microbiome in Inflammatory Bowel Disease and Other Chronic Immune-Mediated Inflammatory Diseases. Inflammatory Intestinal Diseases 2(2): 116-123, 2017

Leucocyte elastase in chronic inflammatory bowel diseases: a marker of inflammatory activity?. Digestion 37(2): 88-95, 1987

Dysplasia in chronic inflammatory bowel diseases. On the standardized classification of the Inflammatory Bowel Disease-Dysplasia Morphology Study Group. Der Pathologe 10(4): 240-243, 1989

Consensus of the Chronic Inflammatory Bowl Disease Study Group of the Austrian Society of Gastroenterology and Hepatology on the topic of "diagnosis and therapy of chronic inflammatory bowel diseases in adolescence". Zeitschrift für Gastroenterologie 38(9): 791-794, 2000

The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129(3): 827-836, 2005

Chronic inflammatory demyelinating polyradiculoneuropathy associated with inflammatory bowel diseases: questioning the autoimmunity hypothesis. International Journal of Colorectal Disease 24(5): 603-604, 2009

Role of inflammatory mediators in anti-inflammatory activity of Withania somnifera on chronic inflammatory reaction. Indian Veterinary Medical Journal 19(2): 150-153, 1995

Fecal alpha 1 antitrypsin and excretion of indium 111 granulocytes in assessing inflammatory activity in chronic inflammatory bowel diseases. Gastroenterologypart 2: 1390, 1987

Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. Current Medical Research and Opinion 35(10): 1751-1759, 2019

Colorectal cancer: screening and surveillance in inflammatory bowel diseases - consensus of the working group for inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology. Zeitschrift für Gastroenterologie 51(5): 450-457, 2014